Use of NGF growth factors to treat drug-induced neuropathy

US5604202A · kind A · utility

Assignee

• Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva University · US

Inventors

• John A. Kessler · New Canaan, US
• Stuart C. Apfel · West Hempstead, US

Key dates

• Filing date: Nov 17, 1993
• Grant date: Feb 18, 1997
• Expiry date: Nov 17, 2013

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/337
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor .varies. (TFG-.varies.), transforming growth factor .beta. (TGF-.beta.) and others to prevent drug-induced neuropathy.